RMD Quote, Financials, Valuation and Earnings

Bio-Rad Laboratories has a net margin of 28.26% compared to ResMed's net margin of 10.93%. ResMed's return on equity of 25.76% beat Bio-Rad Laboratories's return on equity of -29.59%.

ResMed has a consensus price target of $264.49, signalling upside risk potential of 8.8%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $318.67 which suggests that it could grow by 32.22%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.

ResMed has a beta of 0.783, which suggesting that the stock is 21.661% less volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.087999999999999%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.87%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Bio-Rad Laboratories quarterly revenues of $585.4M. ResMed's net income of $365M is higher than Bio-Rad Laboratories's net income of $64M. Notably, ResMed's price-to-earnings ratio is 27.28x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.14x versus 2.66x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 28.26% compared to ResMed's net margin of 14.45%. ResMed's return on equity of 25.76% beat Boston Scientific's return on equity of 9.57%.

ResMed has a consensus price target of $264.49, signalling upside risk potential of 8.8%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.42%. Given that Boston Scientific has higher upside potential than ResMed, analysts believe Boston Scientific is more attractive than ResMed.

ResMed has a beta of 0.783, which suggesting that the stock is 21.661% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.87%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are smaller than Boston Scientific quarterly revenues of $4.7B. ResMed's net income of $365M is lower than Boston Scientific's net income of $674M. Notably, ResMed's price-to-earnings ratio is 27.28x while Boston Scientific's PE ratio is 75.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.14x versus 8.76x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies has a net margin of 28.26% compared to ResMed's net margin of -19.35%. ResMed's return on equity of 25.76% beat iRhythm Technologies's return on equity of -112.03%.

ResMed has a consensus price target of $264.49, signalling upside risk potential of 8.8%. On the other hand iRhythm Technologies has an analysts' consensus of $137.33 which suggests that it could grow by 0.24%. Given that ResMed has higher upside potential than iRhythm Technologies, analysts believe ResMed is more attractive than iRhythm Technologies.

ResMed has a beta of 0.783, which suggesting that the stock is 21.661% less volatile than S&P 500. In comparison iRhythm Technologies has a beta of 1.343, suggesting its more volatile than the S&P 500 by 34.347%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.87%. iRhythm Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. iRhythm Technologies pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than iRhythm Technologies quarterly revenues of $158.7M. ResMed's net income of $365M is higher than iRhythm Technologies's net income of -$30.7M. Notably, ResMed's price-to-earnings ratio is 27.28x while iRhythm Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.14x versus 6.94x for iRhythm Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 28.26% compared to ResMed's net margin of -45.89%. ResMed's return on equity of 25.76% beat Masimo's return on equity of -39.91%.

ResMed has a consensus price target of $264.49, signalling upside risk potential of 8.8%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 18.55%. Given that Masimo has higher upside potential than ResMed, analysts believe Masimo is more attractive than ResMed.

ResMed has a beta of 0.783, which suggesting that the stock is 21.661% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.87%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Masimo quarterly revenues of $372M. ResMed's net income of $365M is higher than Masimo's net income of -$170.7M. Notably, ResMed's price-to-earnings ratio is 27.28x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 7.14x versus 4.22x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.